investorscraft@gmail.com

Stock Analysis & ValuationRenovoRx, Inc. (RNXT)

Previous Close
$0.88
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

4546 El Camino Real
Mountain View, CA 94022
United States
Phone: 650 284 4433
Industry: Biotechnology
Sector: Healthcare
CEO: Shaun R. Bagai
Full Time Employees: 10

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

HomeMenuAccount